@phdthesis{eprintsunpak7880,
          author = {Syafana Zahra Aulia and Bina Lohita Sari and Lusi Agus Setiani},
           title = {Hubungan Kuantitaf Struktur Aktivitas Dan Penambatan Molekul Senyawa Analog O-Metil Kuersetin Sebagai Inhibitor Epidermal Growth Factor Receptor-Tyrosine Kinase (EGFR-TK)},
          school = {Universitas Pakuan},
            year = {2023},
           month = {May},
             url = {http://eprints.unpak.ac.id/7880/},
        abstract = {Quantitative Structure-Activity Relationship and Molecular Docking of O?methyl Quercetin Analogues Compounds as EGFR-TK Inhibitor
Bina Lohita Sari*, Lusi Agus Setiani, and Shafana Zahra Aulia
Department of Pharmacy, Faculty of Mathematics and Natural Sciences, Universitas Pakuan, Bogor, 
West Java, Indonesia.
Abstract: Epidermal Growth Factor Receptor-Tyrosine Kinase (EGFR-TK) is a growth factor 
regulating cell proliferation. Cancer arises from the uncontrolled proliferation of cells. Lung cancer 
stands as one example among the diverse array of cancer types. O-methyl quercetin analogs can be 
potential drug candidate for treating lung cancer. The activity of new compounds can be predicted using 
a Quantitative Structure-Activity Relationship (QSAR) model. The structures were optimized using the 
parameterized method 3 (PM3) and analyzed through multiple linear regression (MLR). Structures of 
new compounds were modified with O-alkylamino and then docked to the EGFR-TK receptor using 
molecular docking. The best QSAR model is expressed as LogIC50 = 23.059 + (7.397 {$\times$} log P) + (0.273 
{$\times$} dipole moment) ? (0.005 {$\times$} heat of formation) ? (0.733 {$\times$} ELUMO) ? (0.501 {$\times$} EHOMO) with statistical 
parameters: R = 0.966; R2 = 0.933; Fcount/Ftable = 3.830; and Q2 = 0.752. The molecular docking results, 
in the form of grid scores for the new compounds (QC6\_7 and QC6\_8), were superior to quercetin base 
don the validated QSAR model, specifically -77.699 kcal/mol and -79.458 kcal/mol, respectively. Both 
compounds interact with a key residue of the EGFR-TK receptor, Met769, suggesting their potential as 
drugs for lung cancer.
A R T I C L E H I S T O R Y
Received: 
Revised: 
Accepted: 
DOI: 
Keywords: QSAR, Quercetin Analogs, Molecular Docking, EGFR-TK, Lung Cancer}
}